

RESEARCH ARTICLE

B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells

Yidan Zhi¹, Zhirong Mou^{1*}, Jun Chen², Yujun He³, Hui Dong¹, Xiaolan Fu¹, Yuzhang Wu^{1*}

1 Institute of Immunology of PLA, Third Military Medical University, Chongqing, China, **2** Department of General surgery, Southwest Hospital, Chongqing, China, **3** Department of General surgery, Daping Hospital, Chongqing, China

* wuyuzhang@yahoo.com (YW); mouZR@yahoo.com (ZM)



OPEN ACCESS

Citation: Zhi Y, Mou Z, Chen J, He Y, Dong H, Fu X, et al. (2015) B7H1 Expression and Epithelial-To-Mesenchymal Transition Phenotypes on Colorectal Cancer Stem-Like Cells. PLoS ONE 10(8): e0135528. doi:10.1371/journal.pone.0135528

Editor: Giuseppe Pirozzi, Istituto Nazionale Tumori, ITALY

Received: March 8, 2015

Accepted: July 22, 2015

Published: August 18, 2015

Copyright: © 2015 Zhi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This work was supported by National Natural Science Foundation of China (to ZM, No. 30872466), National Program on Key Basic Research Project (973 Program) of China (to ZM, No. 2010CB529404). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Cancer stem cells (CSCs) can invade and metastasize by epithelial-to-mesenchymal transition (EMT). However, how they escape immune surveillance is unclear. B7H1 is crucial negative co-stimulatory molecule but little information about whether it works in CSCs. Therefore, we determined the expression of B7H1 and EMT-associated markers in colorectal cancer stem-like cells to investigate a possible immunoevasion way of CSCs. We enriched CD133⁺ colorectal cancer cells which manifested the CSCs-like properties such as higher levels of other stem cell markers Oct-4 and Sox-2, tumor sphere forming ability and more tumorigenic in NOD/SCID mice. These CD133⁺ cells possess EMT gene expression profile including higher level of Snail, Twist, vimentin, fibronectin and lower level of E-cadherin. Moreover, CD133⁺ cells in both cell line and colorectal cancer tissues expressed high level of negative co-stimulate molecule B7H1. Furthermore, some B7H1⁺ cancer cells also showed the characteristic of EMT, indicating EMT cells could escape immune attack during metastasis. B7H1 expression and EMT phenotypes on CSCs indicates a possible immunoevasion way.

Introduction

Colorectal cancer is the third most commonly diagnosed cancer in males and the second one in females [1], but advancements of anti-cancer therapy have been made limitedly in the past 50 years. Failure of anti-cancer therapy is attributed to a subpopulation of cancer cells called cancer stem cells (CSCs), which are the putative cancer-initiating cells with the characteristics of normal stem cells, such as self-renewal, multipotency and limitless proliferation potential [2]. Moreover, CSCs are thought to be crucial for drug-resistance [3]. Therefore, it is believed that CSCs are the “seeds” of cancer formation and difficult to be eliminated. Colorectal CSCs have also been isolated and characterized based on CSCs markers such as CD133 [4–9].

CSCs play a crucial role in cancer invasion and metastasis. To understand how cancer cells metastasize, the role of the epithelial-to-mesenchymal transition (EMT) has been extensively

studied over the past decade. EMT confers invasive and metastatic characteristics, resistance to therapies, and CSCs phenotypes on cancer cells in experimental models [10–15]. Cancer cells undergoing EMT downregulate the proteins associated with cell adhesion, such as E-cadherin, and upregulate proteins expressed on mesenchymal cells, such as vimentin, N-cadherin and fibronectin [13], and transcription factors including *Snail*, *Twist*, and *Slug* as well [16]. EMT also facilitates cancer cell survival after treatment with anti-cancer drugs, which target receptors on epithelial cells [12, 17]. In addition, induction of EMT in cancer cells with drugs or overexpression of EMT transcription factors results in acquisition of mesenchymal properties and in expression of stem-cell markers [18–20]. On the other hand, cancer cells following treatment with anti-cancer drugs, which have been shown to enrich CSCs, manifest the phenotypes and gene expression like EMT [21]. These findings indicate the close association between CSCs and the acquisition of EMT. However, a majority of pathologists are still refractory to the EMT theory because definitive proof of EMT happening in human tumors is lacking so far.

CSCs possess intrinsic biological characteristics to form tumor and may invade tissues through EMT. But it is unclear that how they evade immune surveillance for final survival in immunocompetent hosts. Immuno-evasion may help CSCs to survive and then form tumor [3]. Previous reports have suggested inherent connections between immune suppression and EMT, such as that Snail-induced EMT induced regulatory T cells and impaired dendritic cells [22]. Taken together, we hypothesize immuno-evasion is important for CSCs that undergo EMT through paraneoplastic inflammation region without immune clearance and then implement invasion and metastasis. However, data is still scarce of the immuno-evasion mechanisms in CSCs [3].

B7H1, a ligand of programmed cell death 1 (PD-1), has been well-known as a crucial co-stimulatory molecule and plays an important role in the induction and maintenance of peripheral tolerance [23]. B7H1 is upregulated on considerable kinds of cancer cells which offers negative signals and leads to immunosuppression through PD-1-B7H1 interaction between cancer cells and T cells [24, 25], resulting in tumor-infiltrating T cells dysfunction and Treg recruitment [26]. These traits make B7H1 become a promising target to control cancer. Nevertheless, B7H1 expression on CSCs is not known well in colorectal cancer. Thus, we detected B7H1 expression in colorectal cancer in this study and showed B7H1 expression and EMT phenotypes on colorectal cancer stem-like cells, which might be mechanisms for CSCs to escape immune surveillance and invade distant tissues.

Materials and Methods

Ethics statement

The human colorectal cancer tissues were obtained from the Southwest Hospital under ethical protocols approved by the Ethics Committee of the Third Military Medical University, Chongqing, China. All patients provided written informed consent. Animal experiments were approved by the Institutional Animal Care and Use Committee of the Third Military Medical University. All procedures were in compliance with the National Institute of Health Guide for Care and Use of Laboratory Animals.

Cancer tissues and cell Line

The human colorectal tumors were histopathologically evaluated and classified by the Tumor-Node-Metastasis (TNM) staging system (Table 1). The colon cell line HT29 cells (Catalog number: TCHu 103, purchased on May 29th, 2010 from the Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultured in McCoy's 5A (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA).

Table 1. Patients' information and cancer characteristics.

| Case | Age/Sex | Site | TMN stage |
|------|---------|--------|-----------|
| 1 | 69/M | Right | T2N0M0 |
| 2 | 58/M | Right | T3N0M0 |
| 3 | 74/M | Left | T3N0M0 |
| 4 | 59/F | Right | T3N0M0 |
| 5 | 63/M | Right | T3N0M0 |
| 6 | 59/F | Rectum | T3N0M0 |
| 7 | 37/F | Rectum | T3N0M0 |
| 8 | 68/M | Sigma | T3N0M0 |
| 9 | 56/F | Left | T3N0M0 |
| 10 | 74/F | Sigma | T3N0M0 |
| 11 | 69/M | Left | T3N0M0 |
| 12 | 56/F | Right | T3N0M0 |
| 13 | 56/M | Right | T3N0M0 |
| 14 | 59/F | Right | T3N0M0 |
| 15 | 58/F | Left | T4N0M0 |
| 16 | 76/M | Sigma | T4N2M1 |
| 17 | 76/M | Sigma | T4N2M0 |
| 18 | 55/M | Right | T4N2M0 |
| 19 | 70/M | Sigma | T4N2M0 |
| 20 | 49/M | Right | T4N2M1 |

doi:10.1371/journal.pone.0135528.t001

Magnetic cell sorting

HT29 cells were harvested at exponential growth phase with 0.25% trypsin (contained EDTA) then sorted by CD133 Cell Isolation Kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the instructions of manufacturer. The dead cells were removed by Dead Cell Removal Kit (Miltenyi Biotec) before sorting. The CD133⁺ and CD133⁻ fractions were collected separately and stained with PE-conjugated human CD133/2 (293C3) antibody (Miltenyi Biotec). PE-conjugated mouse IgG2b (Miltenyi Biotec) was used as isotype control antibody. The cell purity was assessed by flow cytometry (BD FACSCanto II, San Jose, CA, USA).

Tumorigenic assays in mice

NOD/LtSz-scid/scid (NOD/SCID) mice (Purchased from Beijing Laboratory Animal Research Center, China) were bred and maintained in Individual Ventilated Caging System under conditions approved by the Institutional Animal Care and Use Committee of the Third Military Medical University. CD133⁺ and CD133⁻ cells were sorted and counted before inoculation. Cancer cells were suspended in a 1:1 mixture of media and matrigel (BD Biosciences, Bedford, UK) and injected subcutaneously into the flanks of 4 mice (about 8–10 weeks of age). Each flank was injected 1×10^4 cells. The growth of tumors was monitored weekly and measured the volume by $\text{length} \times \text{width} \times \text{width} / 2$. All mice were sacrificed after 7 weeks transplantation. The xenografts were removed, fixed with 10% buffered formalin, and stained with hematoxylin and eosin (HE).

Sphere formation assay

The sorted CD133⁺ and CD133⁻ cells were cultured in serum-free medium (NS-A basal medium, Stemcell Technologies, Vancouver, BC, Canada) plus 10% NS-A Proliferation

Supplements (Human) (Stemcell Technologies), epidermal growth factor(EGF)(20 ng/mL) (Stemcell Technologies), basic fibroblast growth factor (bFGF)(10 ng/mL) (Stemcell Technologies) and heparin (2 µg/mL) (Invitrogen). The culture medium was replaced every 3 days. The images of spheres were captured after 20 days by microscope and counted numbers under 100×magnification in random visual fields. Some spheres were stained with PE-conjugated CD133/2 (293C3) antibody (Milteny Biotect). Some tumor spheres were dissociated by Collagenase Type IV(Sigma-Aldrich, St Louis, MO, USA) and then cultured in serum-free medium as mention above to determine whether spheres could form again.

RNA extraction, cDNA synthesis, and Q-PCR

CD133⁺ and CD133⁻ HT29 cells were collected respectively and added Tripure (Roche Diagnostics, Indianapolis, IN, USA) to extract RNA. 500 ng RNA for each sample was reversely transcribed in a 20 µL reaction mixture (TOYOBO Bio-Technology, Shanghai, China). Expression level of each gene was determined by real-time quantitative PCR (Q-PCR). Level of product was determined by SYBR Green (TAKARA Biotechnology, Dalian, China). Q-PCR was performed by Mx3000P qPCR system (Agilent Technologies) with the following program: initial denaturation for 2 minutes at 95°C followed 45 cycles of PCR (95°C for 10 seconds, 60°C for 30 seconds, 72°C for 30 seconds). After that one cycle designed by Mx3000P software (95°C for 60 seconds, 55°C for 30 seconds, 95°C for 30 seconds) was added for melting curve analysis. Primer sequences were listed in Table 2. Glyceraldehyde phosphate dehydrogenase(GAPDH) was used as the housekeeping gene control.

Immunofluorescence staining

The frozen sections of cancer tissues were stained according to online protocol (http://www.ihcworld.com/_protocols/general_IHC/immunofl.htm). Antibodies against human CD133, B7H1, E-cadherin and vimentin were used to determine the expression of EMT markers on CD133 positive or B7H1 positive cells. Similarly, antibodies against human CD133, B7H1 and EpCAM were used to detect CD133 and B7H1 expression on cancer tissues. The details of antibodies selection were listed in Table 3. Secondary antibodies were purchased from Beyotime Institute Biotechnology, Shanghai, China. Diamidino-phenyl-indole (DAPI) (Beyotime Biotechnology) was used to stain nucleus. Controls included: 1) Blank: used antibody dilution buffer (5% bovine serum albumin in phosphate-buffer saline, pH 7.2) only; 2) Negative control: used antibody dilution buffer plus secondary antibodies; 3) Isotype antibody control: used IgG from antibody species diluted by antibody dilution buffer plus secondary antibodies. Controls were used to avoid nonspecific fluorescence.

Table 2. Primers used for Real-time PCR.

| Gene name | Forward(5'-3') | Reverse(5'-3') |
|-------------|--------------------------|-------------------------|
| Oct-4 | CCTGAAGCAGAAGAGGATC | CGTTTGCTGAATACCTT |
| Sox-2 | CCAGCTCGCAGACCTACAT | ACTTGACCACCGAACCCA |
| Snail | CCAGTGCCTCGACCACTATG | GCAGCTCGCTGTAGTTAGGCTTC |
| Twist | GGCCAGGTACATCGACTTCC | CCGCTCGTGAGCCACATA |
| E-cadherin | CAGCACGTACACAGCCCTAA | ACCTGAGGCTTTGGATTCTT |
| Vimentin | GACAATGCGTCTCTGGCACGTCTT | TCCTCCGCTCCTGCAGGTTCTT |
| Fibronectin | CAGGATCACTTACGGAGAAACAG | GCCAGTGACAGCATAACACAGTG |
| GAPDH | GCACCGTCAAGGCTGAGAAC | TGGTGAAGACGCCAGTGA |

doi:10.1371/journal.pone.0135528.t002

Table 3. Antibodies list of immunofluorescence staining.

| Fig. No. | Primary antibodies | Secondary antibodies |
|---|--|---------------------------|
| Fig 3A | Mouse anti-human CD133 (Miltenyi Biotec) | Goat anti-mouse IgG-Cy5 |
| | Rabbit anti-human E-cadherin (Santa Cruz) | Goat anti-rabbit IgG-FITC |
| Fig 3B | Rabbit anti-human CD133 (Abcam) | Goat anti-rabbit IgG-FITC |
| | Mouse anti-human vimentin (Santa Cruz) | Goat anti-mouse IgG-Cy5 |
| Fig 3C | PE-conjugated mouse anti-human CD133 (Miltenyi Biotec) | - |
| | Rabbit anti-human E-cadherin (Santa Cruz) | Goat anti-rabbit IgG-FITC |
| | Mouse anti-human vimentin (Santa Cruz) | Goat anti-mouse IgG-Cy5 |
| Fig 4A | PE-conjugated mouse anti-human CD133 (Miltenyi Biotec) | - |
| | Mouse anti-human B7H1 (provided by Prof. Lieping Chen, Yale University, USA) | Goat anti-mouse IgG-FITC |
| Fig 4B (C) S1 Fig | Rabbit anti-human CD133 (Abcam) | Goat anti-rabbit IgG-Cy3 |
| | Mouse anti-human B7H1 (as in Fig 4A) | Goat anti-mouse IgG-FITC |
| | APC-conjugated mouse anti-human EpCAM (Miltenyi Biotec) | - |
| Fig 5A | Mouse anti-human B7H1 (as in Fig 4A) | Goat anti-mouse IgG-Cy5 |
| | Rabbit anti-human E-cadherin (Santa Cruz) | Goat anti-rabbit IgG-FITC |
| Fig 5B | Rabbit anti-human B7H1 (Santa Cruz) | Goat anti-rabbit IgG-FITC |
| | Mouse anti-human vimentin (Santa Cruz) | Goat anti-mouse IgG-Cy5 |

doi:10.1371/journal.pone.0135528.t003

HT29 cells staining protocol was similar to cancer tissues, but before that cells were seeded onto poly-L-lysine (Sigma-Aldrich) pre-coated-cover slips, cultured in McCoy's 5A medium for 24 h and then fixed with Fixation and Permeabilization Solution (BD Biosciences).

After staining, all slides were kept in humidified chambers away from light at 4°C till image capture.

Images capture and expression analysis

All confocal images were captured by laser scanning confocal fluorescence microscope (Leica TCS-SP5, Germany). Controls were used to adjust proper capture condition to avoid non-specific fluorescence interference. The same marker in different slides was detected under the same condition. Expression rates were measured by counting corresponding positive cells in the capture images. Each slide was measured more than 5 fields and counted at least 1000 cells.

Statistical analysis

The differences of xenograft volumes, sphere numbers and mRNA expression level between CD133⁺ and CD133⁻ cells were analyzed by Student's *t*-test. A *p*-value < 0.05 was considered significant difference. All statistical analyses were performed using SPSS software (version 13.0).




Fig 1. CD133⁺ HT29 cells have higher tumorigenic potential and tumor sphere forming ability. HT29 cells were purified with CD133 magnetic beads. The purity of CD133⁺ cells was determined by flow cytometry (A). 1×10^4 CD133⁺ and CD133⁻ cells were subcutaneously injected into the different flanks of NOD/SCID mice. Growth curve of xenograft tumors in NOD/SCID mice shows different capability of tumorigenesis in two subpopulations (B). The kinetics of tumor size was monitored once a week ($n = 4$, mean \pm SD, **, $p < 0.01$). A representative of mice is shown at 7 weeks after inoculation (C). The sections of xenografts (D) from CD133⁺ cells (left, 200 \times magnification) and CD133⁻ cells (right, 200 \times magnification) were analyzed with hematoxylin and eosin stain (bar = 100 μ m). CD133⁺ cells show much more powerful of sphere formation than CD133⁻ ones (E). The histogram shows numbers of spheres derived from different subpopulations (**, $p < 0.01$). Tumor spheres express CD133 (F, top: neutral light; bottom: fluorescence, red; bar = 100 μ m). After dissociation, cells formed spheres again (G, bottom) in serum-free culture medium like their elder generation (G, top) (bar = 100 μ m).

doi:10.1371/journal.pone.0135528.g001

Results

CD133⁺ cells possess more tumorigenic potential and tumor sphere forming ability

As the debates of CSCs markers still exist [27, 28], we checked the cancer stem-like characteristics of sorted CD133⁺ cells first. CD133⁺ and CD133⁻ HT29 cells were collected for determining the cell tumorigenicity. The percentage of CD133⁺ cells was about 90% (Fig 1A). Ten thousands of CD133⁺ and CD133⁻ were subcutaneously injected into the different flanks of NOD/SCID mice. From 5 weeks after injection, the tumors derived from CD133⁺ cells started to be significantly larger than the ones derived from CD133⁻ cells (Fig 1B and 1C). The CD133⁺ cell xenografts showed malignant histology like colon cancer (Fig 1D), suggesting that CD133⁺ cells are more tumorigenic. In addition, sphere formation is one of traits of CSCs [4], we determined sphere formation of CD133⁺ cells and found that CD133⁺ cells formed significantly more tumor spheres than CD133⁻ cells in serum-free culture medium *in vitro* (Fig 1E).




Fig 2. mRNA levels of stem cells markers and EMT associated molecules in CD133⁺ and CD133⁻ HT29 cells. Relative mRNA expression levels of stem cell markers Oct-4 and Sox-2 (A), EMT associated transcription factors Twist and Snail (B), and EMT markers E-cadherin, fibronectin, and vimentin (C) were determined by Real-time quantitative PCR and normalized to GAPDH expression. *, $p < 0.05$; **, $p < 0.01$.

doi:10.1371/journal.pone.0135528.g002

Moreover, almost all cells in CD133⁺ cells derived tumor spheres expressed high level of CD133 (Fig 1F). In addition, after cell dissociation with collagenase, the cells could form tumor spheres again in serum-free medium (Fig 1G), indicating the self-renewal capacity of CD133⁺ cells. Overall, these results indicated that CD133⁺ cells possessed CSCs-like properties.

CD133⁺ HT29 cells express both stem cell-associated and EMT-associated molecules

CSCs are the putative cancer-initiating cells with the characteristics of normal stem cells expressing pluripotency markers, such as Sox-2 and Oct-4 [29–31]. To determine whether CD133⁺ HT29 cells also express those stem cell-associated factors, the transcriptional level of Oct-4 and Sox-2 expression was measured. As expected, two stem cell markers Oct-4 and Sox-2 were expressed significantly higher in CD133⁺ subpopulation ($p < 0.05$) than CD133⁻ cells (Fig 2A), which is consistent with Oct-4 and Sox-2 overexpression in poorly differentiated tumors [32].

Previous study showed that EMT is involved in the conversion of early stage tumors into invasive malignancies [33]. Interestingly, accumulating evidences indicate that induction of EMT phenotypes by different factors also induces CSC-like cells [15]. However, it is not clear whether CSCs display EMT phenotypes. To address this question, expression of EMT-associated molecules in HT29 cells was detected, including transcription factors Snail and Twist, epithelial protein E-cadherin, mesenchymal markers vimentin and fibronectin. CD133⁺ cells




Fig 3. CD133⁺ cancer cells have the EMT phenotypes in colorectal cancer tissues. The expression of CD133 (red), E-cadherin (green) (A) or CD133 (red) and vimentin (green) (B) or CD133 (red), E-cadherin (green) and vimentin (blue) (C) were determined by immunofluorescence staining. The nucleuses were stained with DAPI (A, B: blue; C: grey). It is shown a representative of colon moderately differentiated adenocarcinoma, T3N0M0. (Bar = 20 μm)

doi:10.1371/journal.pone.0135528.g003

expressed significantly higher levels of Snail, Twist, vimentin and fibronectin than CD133⁻ cells ($p < 0.05$) (Fig 2B and 2C). Conversely, E-cadherin expression in CD133⁺ cells was significantly lower ($p < 0.05$) (Fig 2C), indicating CD133⁺ cells manifested EMT-associated characteristics.

CD133⁺ cells in patient tissues display EMT phenotypes

Although EMT was widely studied *in vitro*, the key question about EMT was that the direct evidence of this phenomenon happening in human cancer tissues was lacking. To address this issue, expression of CD133 and EMT-phenotypic molecules was analyzed in human colorectal cancer tissues. CD133 was expressed dispersedly beside the adenocarcinoma nest (Fig 3) but not in para-neoplastic tissue (S1 Fig). Interestingly, we found that some CD133⁺ cells expressed vimentin (Fig 3B) but not E-cadherin in 13/20 detected human colorectal cancer tissues (Fig 3A). By staining these three molecules on the same section, we confirmed a portion of CD133⁺ cells in different samples (20%-40% in total CD133⁺ cells) showed this phenotype (Fig 3C). It indicated the direct evidence that some CD133⁺ cancer stem-like cells had EMT phenotypes in human cancer tissues.

Co-expression of B7H1 and CD133 in HT29 cell line and colorectal cancer tissues

To investigate the mechanism how CSCs escape immune surveillance, B7H1 expression was determined in HT29 cell line and colorectal cancer tissues. We found that co-expression of




Fig 4. Co-expression of B7H1 and CD133 in HT29 cells and colorectal cancer tissues. The expression of CD133 (red) and B7H1 (green) in HT29 cells (A) (Bar = 20 μ m), and expression of EpCAM (blue), CD133 (red) and B7H1 (green) in colorectal cancer tissues (B) (Bar = 50 μ m) were determined by immunofluorescence staining. The nuclei were stained with DAPI (grey). The rectangle area in the image is enlarged (C) and shows a typical co-expression of CD133 and B7H1 (indicated with arrows). It is shown a representative rectal moderately differentiated adenocarcinoma, T3N0M0.

doi:10.1371/journal.pone.0135528.g004

B7H1 and CD133 was ubiquitous in HT29 cells (Fig 4A). To further determine B7H1 expression in patient tissues, colorectal cancer tissues were collected. EpCAM, a luminal epithelial marker, was used to distinguish cancer nests and stromal region [34]. We found that B7H1 was expressed mainly in cancer cells in more than half (11/20) of colorectal cancer tissues (Table 4). More interestingly, about 50% of CD133 expressing cancer cells expressed B7H1 (Fig 4B and 4C, Table 4). Moreover, B7H1 and CD133 were always co-expressed in EpCAM⁺ cells (Fig 4B and 4C). It indicates CD133⁺ CSCs might escape immune surveillance by expressing inhibitory molecule B7H1.

B7H1 expressing cells display EMT phenotypes in colorectal tissues

We found that B7H1 was expressed on CD133⁺ cells and might play a role in immunoevasion of cancer stem-like cells. It would be interesting to know whether B7H1 expression is related to EMT. To address this directly, B7H1 expression in EMT phenotypic cells was determined in 11 human colorectal cancer samples in which CD133 was co-expressed with B7H1. Similar to previous studies [35], B7H1 was expressed on cancer cells especially on the edge of cancer (Fig 5). In these cases, especially where it looked like tumor budding, we found that 20%-40% of

Table 4. B7H1 and CD133 expression on human colorectal cancer tissues.

| <i>TMN stage</i> | <i>Number of samples tested</i> | <i>Cases of B7H1 expressed on cancer cells</i> | <i>Percentage of B7H1 expression on CD133⁺ cells</i> |
|------------------|---------------------------------|--|---|
| T2MON0 | 1 | 0 | - |
| T3MON0 | 13 | 7 | (53±23) ^{##} |
| T4M0-2N0-2 | 6 | 4 | (45±29) ^{\$\$} |

##: data was obtained from 7 cases of B7H1 expressed on cancer cells in T3MON0 stage.

\$\$: data was obtained from 4 cases of B7H1 expressed on cancer cells in T4M0-2N0-2 stage.

doi:10.1371/journal.pone.0135528.t004

B7H1 expressing cancer cells down-regulated E-cadherin (Fig 5A). Furthermore, 10%-25% of B7H1⁺ cancer cells expressed vimentin, a mesenchymal marker (Fig 5B), indicating EMT phenotype exist in certain B7H1⁺ cells. Taken together, it suggested that overexpression of B7H1 might be one of immunoevasive mechanisms not only for CD133⁺ CSCs, but also for transient EMT phenotypic cancer cells.

Discussion

CSCs are considered to be the “seeds” of cancers and can be enriched by cell sorting based on some specific surface markers. Though the markers of CSCs are still disputable, cancer cells expressing certain specific molecules display CSCs-like the properties [9]. CD133 is one of markers of hematopoietic stem cells and considered to be a CSCs marker in colorectal cancer [5–7, 27, 28, 36]. In this study, CD133⁺ cells had CSCs-like characteristics by showing capability of sphere forming and tumorigenicity, expressing higher levels of stem cell markers Oct-4 and Sox-2 which were overexpressed in poorly differentiated tumors [29, 31]. Moreover, these cells manifested EMT gene expression profile, which had been considered to be an important peculiarity linking to CSCs [15].

Our results of the CSCs-like traits of CD133⁺ cells were consistent with previous studies [5–7]. In contrary, there are some other results showed that CD133 negative cells possessed CSCs-like properties instead [27, 28]. For example, a CD133 negative cell line (NANK) was established from xenografts which derived from fresh surgical samples of human colonic primary and its ovarian metastatic cancer tissues transplanted into NOD/SCID mice [28]. NANK cells possessed CSCs-like characteristics such as sphere formation and tumorigenicity in NOD/SCID mice. Compared with our study, it can be found that the origin of cancer cells were quite different, which might interfere the consistency of results. Moreover, NANK cells differed from their original cancer as well, such as that CD133 and CD44 were expressed in original cancer but rather weakly in NANK. Therefore, it seems that this contrast implies the complex of cancer rather than the mistakes of research methods. Though it's not rigorous enough to use CD133 alone to identify CSCs, it's confirmed that CSCs were enriched in CD133⁺ subpopulation and made it display CSCs-like features. It's interesting and valuable to explore the traits of this subpopulation.

CD133⁺ colorectal cancer cells in both cell line and cancer tissues manifested the characteristics made them special and easier to invade and metastasize. In this study, we found that CD133⁺ HT29 cells showed EMT phenotypes and co-expressed B7H1, indicating CSCs may express B7H1 to evade immune surveillance when they invade through EMT. Similar to HT29 cells, CD133 expression level in colorectal cancer tissues was variable in different cells. Previous studies showed that CD133 was expressed on cancer cells but not haemocytes [4, 5] and most carcinoma cells expressed a membrane glycoprotein EpCAM [34], which is considered as one of CSC markers in several carcinoma types [37]. We found that CD133 was expressed on




Fig 5. Some B7H1 expressing cells manifest the feature like EMT in colorectal cancer tissues. The expression of B7H1 (green) and E-cadherin (red) (A) or B7H1 (green) and vimentin (red) (B) were determined by immunofluorescence staining. One of B7H1 expressing cells is indicated with an arrow. The nucleuses were stained with DAPI (blue). It is shown a representative of colon moderately differentiated adenocarcinoma, T3N0M0. (Bar = 20 μ m)

doi:10.1371/journal.pone.0135528.g005

EpCAM⁺ cells (Fig 4), indicating those CD133 expressing cells are colorectal cancer cells. Though EMT is indicated as the characteristic of CSCs, whether there is inherent connection

between them remain unclear. In previous studies, CSCs-like cells could be generated by induced EMT activation in cell lines or mouse model [19, 38]. Thus, we thought that similar phenomenon might exist in colorectal cancer. In the current experiment, confocal microscope was used to detect different markers expression in cancers, which could observe several proteins expression in each cell simultaneously. As expected, we found that CD133⁺ cells in human colorectal cancer tissues had EMT phenotypes, downregulating E-cadherin and upregulating vimentin. This phenomenon happened in a portion of CD133 positive cells, which might be concerned with the reason that EMT was a dynamic course and hard to catch the switch. Taken together, our results indicate the direct connection between CSCs and EMT in colorectal cancer tissues.

CSCs have intrinsic biological characteristics to form tumor and may metastasize through EMT. It would be interesting to determine how they evade immune surveillance for final survival especially in immunocompetent hosts. B7H1 is a crucial negative co-stimulatory molecule leading to immunoevasion in cancers. B7H1 expression on CD133⁺ cancer cells indicates that B7H1 may play a role in CSCs. Recently clinical trails showed that blocking PD-1-B7H1 pathway results in relative good prognosis in anti-cancer therapy and B7H1 expression in cancer tissues is associated with outcome of the treatment [39]. Based on what we found here, this remarkable outcome might be related to control CSCs by targeting PD-1-B7H1 pathway. B7H1 is considered a better target than another negative co-stimulating molecule, CTLA-4, because the distribution of B7H1/PD-1 axis is within the tumor microenvironment more selectively [40, 41]. Our results suggest that targeting B7H1 might hurt the “prime culprit” of cancer, cancer stem cells, in colorectal cancer. Moreover, some B7H1⁺ manifested EMT-like phenotype, hinting the potential connection of immunoevasion and EMT. In transgenic mice model, it had been proved that upregulation of B7-H1 in skin epithelial cells promoted EMT and accelerates carcinogenesis [42], which was consistent with our finding that B7H1 expressing cancer cells had EMT phenotypes in colorectal cancer tissues.

Taken together, our results showed B7H1 expression and EMT phenotypes in CD133⁺ cells, indicating the potential mechanisms for CSCs to escape immune surveillance and invade distant tissues. Though some studies doubt about CD133 for CSCs' marker, our results suggest that in CD133⁺ subpopulation included a section of cells possesses characteristics helping cells invade and metastasize, especially in which manifest EMT phenotypes and express B7H1. Such a small section of cancer cells have powerful tumorigenicity and could invade and metastasize without immune attack, which may close to the theoretic CSCs in functional aspects. Nevertheless, it is still uncertain whether EMT and B7H1 expression of CSCs are two independent events or regulated by the same signaling pathway at the same time. It was shown that mTOR signal and hypoxia-inducible factor -1 α , which was an important factor to induce EMT, regulated CD133 expression in cancer cells [43], indicating that CD133 expression and EMT phenotypes were related to hypoxia and might be regulated by mTOR signal. Moreover, B7H1 was regulated by PTEN through the PI3K/AKT/mTOR signaling in pancreatic cancer [44]. These studies suggested that mTOR signaling might be involved in the relationship between EMT and immune evasion in CSCs. Thereafter, we are trying to find out the important pathway concerned with EMT and immunevasion in CSCs in further study, which may be a crucial target in cancer therapy.

Supporting Information

S1 Fig. CD133 is scarcely expressed in paraneoplastic tissue. Immunofluorescence of frozen section of colon cancer sample shows that there is a region of relative normal beside cancer nests, where CD133 (red) is rather weaker (left) than in cancer nest (right). DAPI (grey) was

used to stain nuclear. It is shown a representative of colon moderately differentiated adenocarcinoma, T3N0M0. (Bar = 50 μ m)
(TIF)

Acknowledgments

We thank Dr Yongwen Chen for insightful comments, Prof. Lieping Chen for B7H1 antibody and Wei Sun and Liting Wang for excellent technical assistance for image collection by laser scanning confocal fluorescence microscope.

Author Contributions

Conceived and designed the experiments: YW ZM YZ. Performed the experiments: YZ JC YH HD. Analyzed the data: YZ ZM YW. Contributed reagents/materials/analysis tools: JC YH XF. Wrote the paper: YZ ZM YW.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011; 61(2):69–90. Epub 2011/02/08. doi: [10.3322/caac.20107](https://doi.org/10.3322/caac.20107) [pii]; doi: [10.3322/caac.20107](https://doi.org/10.3322/caac.20107) PMID: [21296855](https://pubmed.ncbi.nlm.nih.gov/21296855/).
2. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nature medicine*. 1997; 3(7):730–7. Epub 1997/07/01. PMID: [9212098](https://pubmed.ncbi.nlm.nih.gov/9212098/).
3. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. *The Journal of clinical investigation*. 2010; 120(1):41–50. Epub 2010/01/07. doi: [10.1172/JCI41004](https://doi.org/10.1172/JCI41004) PMID: [20051635](https://pubmed.ncbi.nlm.nih.gov/20051635/); PubMed Central PMCID: PMC2798700.
4. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. *Nature*. 2007; 445(7123):111–5. Epub 2006/11/24. doi: [10.1038/nature05384](https://doi.org/10.1038/nature05384) PMID: [17122771](https://pubmed.ncbi.nlm.nih.gov/17122771/).
5. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature*. 2007; 445(7123):106–10. Epub 2006/11/24. doi: [10.1038/nature05372](https://doi.org/10.1038/nature05372) PMID: [17122772](https://pubmed.ncbi.nlm.nih.gov/17122772/).
6. O'Brien CA, Pollett A, Gallinger S, Dick JE. Expression of CD133 enriches for colon cancer stem cells. *Annals of Surgical Oncology*. 2007; 14(2):22–. PMID: [ISI:000244096200067](https://pubmed.ncbi.nlm.nih.gov/151000244096200067/).
7. Ieta K, Tanaka F, Haraguchi N, Kita Y, Sakashita H, Mimori K, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. *Ann Surg Oncol*. 2008; 15(2):638–48. Epub 2007/10/13. doi: [10.1245/s10434-007-9605-3](https://doi.org/10.1245/s10434-007-9605-3) PMID: [17932721](https://pubmed.ncbi.nlm.nih.gov/17932721/).
8. Todaro M, Francipane MG, Medema JP, Stassi G. Colon Cancer Stem Cells: Promise of Targeted Therapy. *Gastroenterology*. 2010; 138(6):2151–62. doi: [10.1053/j.gastro.2009.12.063](https://doi.org/10.1053/j.gastro.2009.12.063) PMID: [20420952](https://pubmed.ncbi.nlm.nih.gov/20420952/).
9. Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. *Stem Cells*. 2012; 30(3):363–71. Epub 2012/01/11. doi: [10.1002/stem.1031](https://doi.org/10.1002/stem.1031) PMID: [22232074](https://pubmed.ncbi.nlm.nih.gov/22232074/).
10. Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. *Cell stem cell*. 2007; 1(3):241–2. Epub 2008/03/29. doi: [10.1016/j.stem.2007.08.012](https://doi.org/10.1016/j.stem.2007.08.012) PMID: [18371356](https://pubmed.ncbi.nlm.nih.gov/18371356/).
11. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell*. 2008; 133(4):704–15. doi: [10.1016/j.cell.2008.03.027](https://doi.org/10.1016/j.cell.2008.03.027) PMID: [18485877](https://pubmed.ncbi.nlm.nih.gov/18485877/); PubMed Central PMCID: PMC2728032.
12. Hollier BG, Evans K, Mani SA. The Epithelial-to-Mesenchymal Transition and Cancer Stem Cells: A Coalition Against Cancer Therapies. *J Mammary Gland Biol*. 2009; 14(1):29–43. doi: [10.1007/s10911-009-9110-3](https://doi.org/10.1007/s10911-009-9110-3) PMID: [19242781](https://pubmed.ncbi.nlm.nih.gov/19242781/).
13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. *Journal of Clinical Investigation*. 2009; 119(6):1420–8. doi: [10.1172/Jci39104](https://doi.org/10.1172/Jci39104) PMID: [19487818](https://pubmed.ncbi.nlm.nih.gov/19487818/); PubMed Central PMCID: PMC2689101.
14. Kong D, Li Y, Wang Z, Sarkar FH. Cancer Stem Cells and Epithelial-to-Mesenchymal Transition (EMT)-Phenotypic Cells: Are They Cousins or Twins? *Cancers*. 2011; 3(1):716–29. Epub 2011/06/07. doi: [10.3390/cancers30100716](https://doi.org/10.3390/cancers30100716) PMID: [21643534](https://pubmed.ncbi.nlm.nih.gov/21643534/); PubMed Central PMCID: PMC3106306.
15. Biddle A, Mackenzie IC. Cancer stem cells and EMT in carcinoma. *Cancer metastasis reviews*. 2012; 31(1–2):285–93. Epub 2012/02/04. doi: [10.1007/s10555-012-9345-0](https://doi.org/10.1007/s10555-012-9345-0) PMID: [22302111](https://pubmed.ncbi.nlm.nih.gov/22302111/).

16. Strippoli R, Benedicto I, Lozano MLP, Cerezo A, Lopez-Cabrera M, del Pozo MA. Epithelial-to-mesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappa B/Snail1 pathway. *Dis Model Mech*. 2008; 1(4–5):264–74. doi: [10.1242/Dmm.001321](https://doi.org/10.1242/Dmm.001321) PMID: [19093035](https://pubmed.ncbi.nlm.nih.gov/19093035/).
17. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncogene*. 2010; 29(34):4741–51. Epub 2010/06/10. doi: [10.1038/onc.2010.215](https://doi.org/10.1038/onc.2010.215) PMID: [20531305](https://pubmed.ncbi.nlm.nih.gov/20531305/); PubMed Central PMCID: PMC3176718.
18. Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D, et al. Epithelial mesenchymal transition correlates with CD24⁺CD44⁺ and CD133⁺ cells in pancreatic cancer. *Oncol Rep*. 2012; 27(5):1599–605. Epub 2012/02/11. doi: [10.3892/or.2012.1681](https://doi.org/10.3892/or.2012.1681) PMID: [22322379](https://pubmed.ncbi.nlm.nih.gov/22322379/).
19. Zhu LF, Hu Y, Yang CC, Xu XH, Ning TY, Wang ZL, et al. Snail overexpression induces an epithelial to mesenchymal transition and cancer stem cell-like properties in SCC9 cells. *Lab Invest*. 2012; 92(5):744–52. Epub 2012/02/22. doi: [10.1038/labinvest.2012.8](https://doi.org/10.1038/labinvest.2012.8) PMID: [22349639](https://pubmed.ncbi.nlm.nih.gov/22349639/).
20. Santisteban M, Reiman JM, Asiedu NK, Behrens MD, Nassar A, Kalli KR, et al. Immune-Induced Epithelial to Mesenchymal Transition In vivo Generates Breast Cancer Stem Cells. *Cancer Research*. 2009; 69(7):2887–95. doi: [10.1158/0008-5472.Can-08-3343](https://doi.org/10.1158/0008-5472.Can-08-3343) PMID: [19276366](https://pubmed.ncbi.nlm.nih.gov/19276366/).
21. Xue Z, Yan H, Li J, Liang S, Cai X, Chen X, et al. Identification of cancer stem cells in vincristine preconditioned SGC7901 gastric cancer cell line. *Journal of cellular biochemistry*. 2012; 113(1):302–12. Epub 2011/09/14. doi: [10.1002/jcb.23356](https://doi.org/10.1002/jcb.23356) PMID: [21913215](https://pubmed.ncbi.nlm.nih.gov/21913215/).
22. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. *Cancer cell*. 2009; 15(3):195–206. Epub 2009/03/03. doi: [10.1016/j.ccr.2009.01.023](https://doi.org/10.1016/j.ccr.2009.01.023) PMID: [19249678](https://pubmed.ncbi.nlm.nih.gov/19249678/).
23. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. *Annual review of immunology*. 2008; 26:677–704. Epub 2008/01/05. doi: [10.1146/annurev.immunol.26.021607.090331](https://doi.org/10.1146/annurev.immunol.26.021607.090331) PMID: [18173375](https://pubmed.ncbi.nlm.nih.gov/18173375/).
24. Flies DB, Chen L. The new B7s: playing a pivotal role in tumor immunity. *J Immunother*. 2007; 30(3):251–60. Epub 2007/04/07. doi: [10.1097/CJI.0b013e31802e085a](https://doi.org/10.1097/CJI.0b013e31802e085a) PMID: [17414316](https://pubmed.ncbi.nlm.nih.gov/17414316/).
25. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. *J Immunol*. 2003; 170(3):1257–66. Epub 2003/01/23. PMID: [12538684](https://pubmed.ncbi.nlm.nih.gov/12538684/).
26. Hua D, Sun J, Mao Y, Chen LJ, Wu YY, Zhang XG. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. *World J Gastroentero*. 2012; 18(9):971–8. doi: [10.3748/wjg.v18.i9.971](https://doi.org/10.3748/wjg.v18.i9.971) PMID: [22408358](https://pubmed.ncbi.nlm.nih.gov/22408358/); PubMed Central PMCID: PMC3297058.
27. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133(+) and CD133(-) metastatic colon cancer cells initiate tumors. *Journal of Clinical Investigation*. 2008; 118(6):2111–20. doi: [10.1172/Jci34401](https://doi.org/10.1172/Jci34401) PMID: [18497886](https://pubmed.ncbi.nlm.nih.gov/18497886/); PubMed Central PMCID: PMC2391278.
28. Navarro-Alvarez N, Kondo E, Kawamoto H, Hassan W, Yuasa T, Kubota Y, et al. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. *Cell Transplant*. 2010; 19(6):865–77. Epub 2010/07/01. doi: [10.3727/096368910X508997](https://doi.org/10.3727/096368910X508997) PMID: [20587145](https://pubmed.ncbi.nlm.nih.gov/20587145/); PubMed Central PMCID: PMC2957535.
29. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. *PLoS One*. 2011; 6(11):e26740. Epub 2011/11/10. doi: [10.1371/journal.pone.0026740](https://doi.org/10.1371/journal.pone.0026740) PMID: [22069467](https://pubmed.ncbi.nlm.nih.gov/22069467/); PubMed Central PMCID: PMC3206066.
30. Darini CY, Pisani DF, Hofman P, Pedoutour F, Sudaka I, Chomienne C, et al. Self-renewal gene tracking to identify tumour-initiating cells associated with metastatic potential. *Oncogene*. 2012; 31(19):2438–49. Epub 2011/09/20. doi: [10.1038/onc.2011.421](https://doi.org/10.1038/onc.2011.421) PMID: [21927026](https://pubmed.ncbi.nlm.nih.gov/21927026/).
31. Wen K, Fu Z, Wu X, Feng J, Chen W, Qian J. Oct-4 is required for an antiapoptotic behavior of chemoresistant colorectal cancer cells enriched for cancer stem cells: Effects associated with STAT3/Survivin. *Cancer letters*. 2013; 333(1): 56–65. Epub 2013/01/24. doi: [10.1016/j.canlet.2013.01.009](https://doi.org/10.1016/j.canlet.2013.01.009) PMID: [23340171](https://pubmed.ncbi.nlm.nih.gov/23340171/).
32. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. *Nature genetics*. 2008; 40(5):499–507. doi: [10.1038/Ng.127](https://doi.org/10.1038/Ng.127) PMID: [18443585](https://pubmed.ncbi.nlm.nih.gov/18443585/); PubMed Central PMCID: PMC2912221.
33. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and Dissemination Precede Pancreatic Tumor Formation. *Cell*. 2012; 148(1–2):349–61. doi: [10.1016/j.cell.2011.11.025](https://doi.org/10.1016/j.cell.2011.11.025) PMID: [22265420](https://pubmed.ncbi.nlm.nih.gov/22265420/); PubMed Central PMCID: PMC3266542.
34. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. *Hum Pathol*. 2004; 35(1):122–8. doi: [10.1016/S0046-8177\(03\)00502-1](https://doi.org/10.1016/S0046-8177(03)00502-1) PMID: [14745734](https://pubmed.ncbi.nlm.nih.gov/14745734/).

35. Yao Y, Tao R, Wang X, Wang Y, Mao Y, Zhou LF. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. *Neuro-oncology*. 2009; 11(6):757–66. Epub 2009/03/07. doi: [10.1215/15228517-2009-014](https://doi.org/10.1215/15228517-2009-014) PMID: [19264916](https://pubmed.ncbi.nlm.nih.gov/19264916/); PubMed Central PMCID: PMC2802396.
36. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? *The Journal of clinical investigation*. 2008; 118(6):2021–4. Epub 2008/05/24. doi: [10.1172/JCI36046](https://doi.org/10.1172/JCI36046) PMID: [18497883](https://pubmed.ncbi.nlm.nih.gov/18497883/); PubMed Central PMCID: PMC2391070.
37. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. *Nat Rev Cancer*. 2009; 9(2):143–. doi: [10.1038/Nrc2499-C1](https://doi.org/10.1038/Nrc2499-C1) PMID: [19132011](https://pubmed.ncbi.nlm.nih.gov/19132011/).
38. Hollier BG, Tinnirello AA, Werden SJ, Evans KW, Taube JH, Sarkar TR, et al. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer. *Cancer Res*. 2013; 73(6):1981–92. Epub 2013/02/01. doi: [10.1158/0008-5472.CAN-12-2962](https://doi.org/10.1158/0008-5472.CAN-12-2962) PMID: [23378344](https://pubmed.ncbi.nlm.nih.gov/23378344/); PubMed Central PMCID: PMC3602160.
39. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. *New Engl J Med*. 2012; 366(26):2443–54. Epub 2012/06/02. doi: [10.1056/Nejmoa1200690](https://doi.org/10.1056/Nejmoa1200690) PMID: [22658127](https://pubmed.ncbi.nlm.nih.gov/22658127/); PubMed Central PMCID: PMC3544539.
40. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. *Nature medicine*. 2002; 8(8):793–800. Epub 2002/07/02. doi: [10.1038/nm730](https://doi.org/10.1038/nm730) PMID: [12091876](https://pubmed.ncbi.nlm.nih.gov/12091876/).
41. Taube JM, Anders RA, Young GD, Xu HY, Sharma R, McMiller TL, et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. *Sci Transl Med*. 2012; 4(127):127ra37. doi: [10.1126/scitranslmed.3003689](https://doi.org/10.1126/scitranslmed.3003689) PMID: [22461641](https://pubmed.ncbi.nlm.nih.gov/22461641/); PubMed Central PMCID: PMC3568523.
42. Cao Y, Zhang L, Kamimura Y, Ritprajak P, Hashiguchi M, Hirose S, et al. B7-H1 overexpression regulates epithelial-mesenchymal transition and accelerates carcinogenesis in skin. *Cancer Res*. 2011; 71(4):1235–43. Epub 2010/12/17. doi: [10.1158/0008-5472.CAN-10-2217](https://doi.org/10.1158/0008-5472.CAN-10-2217) PMID: [21159661](https://pubmed.ncbi.nlm.nih.gov/21159661/).
43. Matsumoto K, Arai T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. *Cancer Res*. 2009; 69(18):7160–4. Epub 2009/09/10. doi: [10.1158/0008-5472.CAN-09-1289](https://doi.org/10.1158/0008-5472.CAN-09-1289) PMID: [19738050](https://pubmed.ncbi.nlm.nih.gov/19738050/).
44. Yingfei Z, Jianlong Z, Kang X, Zhiyu X, Jian S, Junyao X, et al. PTEN/PI3K/mTOR/B7-H1 Signaling Pathway Regulates Cell Progression and Immunoresistance in Pancreatic Cancer. *Hepato-gastroenterology*. 2013; 60(127):1766–72. PMID: [24624456](https://pubmed.ncbi.nlm.nih.gov/24624456/).